Vinorelbine (Navelbine)

General information

Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase. Vinorelbine may possibly also disrupt: amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent calcium transport ATPase activity; and DNA/RNA and lipid synthesis.^[1]^[2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Disease for which it is used

Patient drug information

History of changes in FDA indication

1994-12-23: Initial FDA approval as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). (Based on Crawford et al. 1996, Le Chevalier et al. 1994, SWOG S9308)

History of changes in EMA indication

1989-04-11: EURD

History of changes in PMDA indication

2005-05-31: New indication for the treatment of inoperable or recurrent breast cancer.

Also known as

Code name: KW-2307
Generic name: NVB, vinorelbine tartrate
Brand names: Binorel, Biovelbin, Eunades, Flonorbin, Navelbine, Neoben, Relbovin, Vinelbine, Vinorelbel, Vinotec

References

[insert-1] 1.0 ^1.1 Vinorelbine (Navelbine) package insert

[2] Vinorelbine (Navelbine) package insert (locally hosted backup)

[3] Vinorelbine (Navelbine) patient drug information (Chemocare)

[4] Vinorelbine (Navelbine) patient drug information (UpToDate)

[1]

[2]

[3]

[4]